Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Raludotatug Deruxtecan · DS-6000A

Antibody-drug conjugate · Cytotoxic, directed at cadherin-6 (CDH6) · developed by Merck Sharp & Dohme LLC

Phase 2 Most advanced trial

MRK Developer

1 Registered trials

What is Raludotatug Deruxtecan?

Raludotatug deruxtecan is an antibody-drug conjugate comprising a humanized anti-CDH6 monoclonal antibody linked to deruxtecan, a DNA topoisomerase I inhibitor. It binds CDH6-expressing tumor cells and delivers the cytotoxic payload, causing DNA breaks and apoptosis. It is studied in lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: DS-6000A, R-DXD
Drug type: Antibody-drug conjugate
Targets: cadherin-6 (CDH6), DNA topoisomerase I (TOP1) (secondary target)
Mechanism: Cytotoxic, directed at cadherin-6 (CDH6)
Pathways: DNA damage, apoptosis
Therapy area: Oncology
Developer: Merck Sharp & Dohme LLC (MRK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: BPQ010OFD7

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06780098	Phase 2	Lung Neoplasm	Recruiting	MRK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lung Neoplasm

More from Merck Sharp & Dohme LLC

BCG Live FDA approved Belzutifan FDA approved Berahyaluronidase Alfa FDA approved Berahyaluronidase Alfa and Pembrolizumab FDA approved Enlicitide FDA approved Ensifentrine FDA approved Letermovir FDA approved Pembrolizumab FDA approved Probenecid FDA approved Alimatravir Phase 2 Bomedemstat Phase 2/3 Calderasib Phase 3

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind Raludotatug Deruxtecan

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z